3-(1-piperidinyl)-N-(2-[3-benzo[b]thienyl]ethyl)pyrrolidine | 158962-42-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: 3-(1-piperidinyl)-N-(2-[3-benzo[b]thienyl]ethyl)pyrrolidine
• 英文别名: 1-[1-[2-(1-Benzothiophen-3-yl)ethyl]pyrrolidin-3-yl]piperidine
• CAS: 158962-42-6
• 化学式: C₁₉H₂₆N₂S
• 分子量: 314.495
• InChiKey: FEAXIWRKKUWCDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  34.7
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Sigma-2 receptor agonists and their use in the treatment of HIV infection
  申请人：Bowen D. Wayne

  公开号：US20060004036A1

  公开（公告）日：2006-01-05

  The present invention relates to sigma-2 receptor agonists and their use in the treatment of immunodeficiency virus infections, especially human immunodeficiency virus (HIV) infections. The invention particularly relates to sigma-2 agonists, especially CB-184 and its analogues, that decrease cellular production of sphingomyelin when provided to recipient cells, and inhibit HIV replication.

  本发明涉及sigma-2受体激动剂及其在治疗免疫缺陷病毒感染，特别是人类免疫缺陷病毒（HIV）感染中的用途。本发明尤其涉及σ-2激动剂，特别是CB-184及其类似物，当提供给受体细胞时，它们能减少细胞产生鞘磷脂，并抑制HIV的复制。
• US5346908A
  申请人：——

  公开号：US5346908A

  公开（公告）日：1994-09-13
• US5656625A
  申请人：——

  公开号：US5656625A

  公开（公告）日：1997-08-12
• US5856318A
  申请人：——

  公开号：US5856318A

  公开（公告）日：1999-01-05
• [EN] MODULATION OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS ACTIVITY<br/>[FR] MODULATION DE L'ACTIVITE DES RECEPTEURS ACTIVES PAR LES PROLIFERATEURS DE PEROXYSOMES
  申请人：CAREX SA

  公开号：WO2004037248A2

  公开（公告）日：2004-05-06

  The present invention relates to compounds, compositions and methods useful for modulating nuclear receptors activity in cells, and for treating and/or preventing various diseases and conditions mediated by said nuclear receptors, including metabolic or cell proliferative disorders. According to particular aspects, the present invention relates to compounds, compositions and methods useful for modulating activities of the Peroxisome Proliferator Activated Receptors (PPARs) and for treating and/or preventing various diseases and conditions mediated by said nuclear receptors. More specifically, it relates to Peroxisome Proliferator Activated Receptor-gamma (PPAR-gamma) ligands, which are useful in the modulation of blood glucose levels and in the increase of insulin sensitivity in patients in need thereof. The properties of the compounds and compositions of the invention make these PPAR ligands particularly useful in the treatment of those diseases and conditions including diabetes, atherosclerosis, hyperglycemia, dyslipidemia, obesity, syndrome X, insulin resistance, hypertension, neuropathy, microvascular diseases (e.g. retinopathy, nephropathy), macrovascular diseases (e.g. myocardial infarction, stroke, heart failure) in mammals.